---
layout: default
title: Vincristine
parent: 僅模型預測 (L5)
nav_order: 665
evidence_level: L5
indication_count: 3
---

# Vincristine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the report format given in the prompt (no separate skill applies — this is a direct document-generation task with explicit instructions already supplied).

# Vincristine: From Hematologic Malignancies and Pediatric Solid Tumors to Ganglioneuroblastoma

## One-Sentence Summary

> Vincristine is a vinca alkaloid antineoplastic long established as a backbone component of combination chemotherapy for leukemias, lymphomas, and pediatric embryonal tumors (the evidence pack does not supply a specific licensed indication text for this drug).
> The TxGNN model predicts it may be effective for **Ganglioneuroblastoma**,
> with **4 clinical trials** and **6 publications** currently supporting this direction, though most of this evidence is indirect (vincristine used as background chemotherapy rather than the primary study drug).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in source data — no licenses or indication text were returned; based on known pharmacology, vincristine is an established antineoplastic used across leukemias, lymphomas, and pediatric solid tumors |
| Predicted New Indication | Ganglioneuroblastoma |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L2 |
| Saudi Arabia Market Status | ✗ Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data was flagged as a gap at the drug level, but the underlying pharmacology is well characterized: vincristine is a vinca alkaloid that binds tubulin and inhibits microtubule polymerization, blocking mitotic spindle formation. This antimitotic activity is preferentially cytotoxic to highly proliferative cell populations, which is why vincristine is a standard-of-care backbone agent (typically combined with cyclophosphamide and doxorubicin) in international pediatric oncology induction protocols (COG/SIOPEN) for high-risk neuroblastoma.

Ganglioneuroblastoma sits on the same neuroblastic tumor spectrum as neuroblastoma — both arise from primitive sympathetic neural crest cells and share overlapping histology, staging, and treatment protocols. The clinical trials identified here (dinutuximab, 131I-MIBG, BuMel consolidation) all enroll high-risk neuroblastoma/ganglioneuroblastoma populations and use vincristine-containing regimens as the induction backbone, which is consistent with — rather than novel evidence for — this predicted use.

Mechanistically, because ganglioneuroblastoma tumors typically retain a proliferative neuroblastic component, the rationale for an antimitotic agent applies directly. However, none of the identified trials test vincristine as the primary investigational agent, so this should be read as confirmatory of existing practice rather than a genuinely new indication.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT03786783](https://clinicaltrials.gov/study/NCT03786783) | Phase 2 | Active, not recruiting | 42 | Pilot induction regimen adding dinutuximab + GM-CSF to standard chemotherapy in newly diagnosed high-risk neuroblastoma; vincristine is part of the background chemo, not the study drug |
| [NCT06172296](https://clinicaltrials.gov/study/NCT06172296) | Phase 3 | Recruiting | 478 | Tests adding dinutuximab to intensive multimodal therapy (which conventionally includes vincristine) in newly diagnosed high-risk neuroblastoma |
| [NCT01798004](https://clinicaltrials.gov/study/NCT01798004) | Phase 1 | Completed | 150 | Myeloablative busulfan/melphalan consolidation following vincristine-containing induction chemotherapy in high-risk neuroblastoma |
| [NCT03126916](https://clinicaltrials.gov/study/NCT03126916) | Phase 3 | Recruiting | 750 | Adds 131I-MIBG or an ALK inhibitor to intensive standard therapy (vincristine-based backbone) in high-risk neuroblastoma/ganglioneuroblastoma |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [31342649](https://pubmed.ncbi.nlm.nih.gov/31342649/) | 2019 | Prospective Cohort/Trial | Pediatric Blood & Cancer | JN-L-10 trial used image-defined risk factors to guide surgical timing, reducing treatment complications in low-risk neuroblastoma |
| [8255850](https://pubmed.ncbi.nlm.nih.gov/8255850/) | 1993 | Case Report | Postgraduate Medical Journal | Spinal ganglioneuroblastoma achieved complete response with vincristine-containing combination chemotherapy alone (no surgery/radiotherapy) |
| [15701990](https://pubmed.ncbi.nlm.nih.gov/15701990/) | 2005 | Case Report | J Pediatr Hematol Oncol | Ganglioneuroblastoma presenting as obstructive jaundice, treated with a cisplatin/anthracycline/cyclophosphamide/vincristine regimen |
| [7421294](https://pubmed.ncbi.nlm.nih.gov/7421294/) | 1980 | Case Series | J Thorac Cardiovasc Surg | 31 patients with intrathoracic ganglioneuroblastoma; outcomes across resection, radiotherapy, and chemotherapy |
| [8888754](https://pubmed.ncbi.nlm.nih.gov/8888754/) | 1996 | Case Report | J Pediatr Hematol Oncol | Rare gastric involvement in an infant with multifocal ganglioneuroblastoma |
| [3071124](https://pubmed.ncbi.nlm.nih.gov/3071124/) | 1988 | Case Report | Acta Urologica Japonica | Multimodality treatment of adult adrenal ganglioneuroblastoma |

---

## Saudi Arabia Market Information

Vincristine is currently **not marketed** in Saudi Arabia — no authorization records were returned (0 licenses on file). Regulatory filing/registration would be a prerequisite before any repurposing pathway could proceed locally.

---

## Cytotoxicity

Vincristine is a conventional cytotoxic chemotherapy agent (vinca alkaloid class), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Conventional cytotoxic — vinca alkaloid, tubulin/microtubule inhibitor |
| Myelosuppression Risk | Low relative to most cytotoxics — vincristine's dose-limiting toxicity is peripheral/autonomic neuropathy rather than bone marrow suppression; confirm against the local package insert once available |
| Emetogenicity Classification | Low (minimally emetogenic per standard IV vinca alkaloid classification) |
| Monitoring Items | CBC with differential, neurological exam (peripheral neuropathy, constipation/ileus from autonomic effects), liver function (dose adjustment in hepatic impairment), infusion-site monitoring |
| Handling Protection | Standard cytotoxic drug handling precautions required. Note: vincristine is a well-established vesicant and is **fatal if administered intrathecally** — this is an independent, drug-class-level safety fact and should be explicitly confirmed against the TFDA package insert once DG001 is resolved |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Proceed with Guardrails**

**Rationale:**
The predicted indication is mechanistically coherent — ganglioneuroblastoma sits on the same neuroblastic tumor spectrum as neuroblastoma, where vincristine is already a guideline backbone agent — but none of the identified trials or literature test vincristine as the primary investigational agent, and the drug is not currently marketed in Saudi Arabia. A Blocking-severity data gap (missing TFDA/package-insert warnings and contraindications) means this candidate cannot yet clear the S1 safety pre-assessment stage.

**To proceed, the following is needed:**
- TFDA package insert (warnings, contraindications) — Blocking gap, required before any S1 safety review
- Confirmed mechanism-of-action documentation from DrugBank (currently marked as a gap at the drug level, though class-level pharmacology was used above)
- Saudi Arabia market registration/licensing pathway, since the drug is currently not marketed locally
- Histopathological stratification of ganglioneuroblastoma subtype, given the heterogeneity of the neuroblastic tumor spectrum, before designing a dedicated trial
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

